key: cord-0275927-lm8yvk7u authors: Savvateeva, E.; Filippova, M.; Valuev-Elliston, V.; Nuralieva, N.; Yukina, M.; Troshina, E.; Baklaushev, V.; Ivanov, A.; Gryadunov, D. title: Microarray-based detection of antibodies against SARS-CoV-2 proteins, common respiratory viruses and type I interferons date: 2021-12-14 journal: nan DOI: 10.1101/2021.12.13.21267509 sha: 6db1f56418a0e550d20500534ac614c32743dca7 doc_id: 275927 cord_uid: lm8yvk7u A microarray-based assay to detect IgG and IgM antibodies against betacoronaviruses (SARS-CoV-2, SARS, MERS, OC43, and HKU1), other respiratory viruses and type I interferons (IFN-Is) was developed. This multiplex assay was applied to track antibody cross-reactivity due to previous contact with similar viruses and to identify antibodies against IFN-Is as the markers for severe COVID-19. In total, 278 serum samples from convalescent plasma donors, COVID-19 pa-tients in the intensive care unit (ICU) and patients who recovered from mild/moderate COVID-19, vaccine recipients, prepandemic and pandemic patients with autoimmune endocrine disorders, and a heterogeneous prepandemic cohort including healthy individuals and chronically ill patients were analyzed. The anti-SARS-CoV-2 microarray results agreed well with the ELISA results. Regarding ICU patients, autoantibodies against IFN-Is were detected in 10.5% of samples, and 10.5% of samples were found to simultaneously contain IgM antibodies against more than two different viruses. Cross-reactivity between IgG against the SARS-CoV-2 nucleocapsid and IgG against the OC43 and HKU1 spike proteins was observed, resulting in positive signals for the SARS-CoV-2 nucleocapsid in prepandemic samples from patients with autoimmune endocrine disorders. The presence of IgG against the SARS-CoV-2 nucleocapsid in the absence of IgG against the SARS-CoV-2 spike RBD should be interpreted with caution. A microarray-based assay to detect IgG and IgM antibodies against betacoronaviruses 16 (SARS-CoV-2, SARS, MERS, OC43, and HKU1), other respiratory viruses and type I interferons 17 (IFN-Is) was developed. This multiplex assay was applied to track antibody cross-reactivity due to 18 previous contact with similar viruses and to identify antibodies against IFN-Is as the markers for 19 severe COVID-19. In total, 278 serum samples from convalescent plasma donors, tients in the intensive care unit (ICU) and patients who recovered from mild/moderate 21 vaccine recipients, prepandemic and pandemic patients with autoimmune endocrine disorders, 22 and a heterogeneous prepandemic cohort including healthy individuals and chronically ill patients 23 were analyzed. The anti-SARS-CoV-2 microarray results agreed well with the ELISA results. garding ICU patients, autoantibodies against IFN-Is were detected in 10.5% of samples, and 10.5% 25 of samples were found to simultaneously contain IgM antibodies against more than two different 26 viruses. Cross-reactivity between IgG against the SARS-CoV-2 nucleocapsid and IgG against the 27 OC43 and HKU1 spike proteins was observed, resulting in positive signals for the SARS-CoV-2 28 nucleocapsid in prepandemic samples from patients with autoimmune endocrine disorders. The 29 presence of IgG against the SARS-CoV-2 nucleocapsid in the absence of IgG against the 30 SARS-CoV-2 spike RBD should be interpreted with caution. pogonadism of autoimmune genesis (n=2), primary autoimmune adrenal insufficiency 98 (n=2), nonautoimmune adrenal insufficiency (n=1), primary hyperparathyroidism (n=1), 99 autoimmune thyroiditis (n=1), and adrenal lymphoma (n=1). 100 Pandemic cohort I-convalescent plasma donors 101 Convalescent plasma donor samples (n=103) were obtained from the Federal Re- 102 search Clinical Center FMBA of Russia (Moscow). Anti-SARS-CoV-2 spike recep-103 tor-binding domain fragment Arg319-Phe541 (RBD) IgG was measured in these samples 104 using both the developed microarray-based multiplex assay and ELISA 105 (SARS-CoV-2-IgG-IFA test, Xema Ltd., Moscow, Russia). 106 Pandemic cohort II-vaccinated individuals and recovered COVID-19 patients 107 To assess the specificity of the anti-SARS-CoV-2 assay, serum samples from indi- perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted December 14, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 Fluorescence images of the microarrays were acquired using a laser-excited analyzer perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in for antibodies against any of the SARS-CoV-2 proteins detected by the microarray, the 226 accuracy and recall increased to 95.1% and 0.91, respectively. 227 perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted December 14, 2021. ; https://doi.org/10. 1101 /2021 The cutoff value for antibodies against SARS-CoV-2 was determined using 22 pre-263 pandemic serum samples from healthy individuals collected before May 2019. For each 264 antibody against SARS-CoV-2 proteins, samples with a fluorescence value greater than 265 three standard deviations above the mean of the healthy prepandemic control samples 266 were classified as positive. Six samples from the prepandemic cohort (n=48), which con-267 tained patients with various pathologies, including autoimmune endocrine disorders, 268 were considered positive for IgG against the SARS-CoV-2 nucleocapsid, and no sample 269 was considered positive for IgG against SARS-CoV-2 spike RBD. In these six samples, 270 IgG against the seasonal coronaviruses OC43 (spike) and HKU1 (spike) were also de- All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted December 14, 2021. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted December 14, 2021. ; https://doi.org/10.1101/2021.12.13.21267509 doi: medRxiv preprint 306 The proportions of positive IgG and IgM antibodies against all respiratory viruses 307 included in the microarray in the prepandemic cohort and in COVID-19 ICU patients 308 were determined using the developed assay ( Figure 6 ). In the COVID-19 ICU patient 309 cohort, the frequencies of antibodies against the seasonal coronaviruses OC43 and HKU1, 310 AdV, RSV, PIV-1, and FluB were increased, and those against PIV-3 and FluA were de- perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in Figure 7 shows the distribution of IgG antibodies against type I IFNs in serum samples of APS-1 patients; in the prepandemic cohort, excluding patients with APS-1; and COVID-19 ICU patients. In 10.5% (9/86) of COVID-19 ICU patients, autoantibodies against type I IFNs were found. However, antibodies against both IFN-ω and IFN-α were detected in only three samples. Two serum samples contained only anti-IFN-ω antibodies, and four samples contained only anti-IFN-α antibodies. Moreover, only 4 of the 9 patients had anti-IFN antibody titers comparable to the high titers of these autoantibodies found in patients with APS-1. In one previously described patient with lymphoma in the prepandemic cohort, both anti-IFN-ω and anti-IFNα antibodies were detected at high titers [13] . In two samples from healthy donors in the prepandemic cohort, anti-IFN antibodies were detected at rather low titers (In/Iref ratios of 2.5 and 3.3, respectively). Figure S1 ). There were similarly high levels of IgG against IFN-α and IFN-ω in both 339 the prepandemic and 2021 APS-1 patient samples. However, in the paired sera (n=5), the 340 signal level was decreased for APS-1 patients who were infected with SARS-CoV-2 (n=4); 341 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted December 14, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 this decrease was not observed in the paired sera from the one patient not exposed to 342 SARS-CoV-2. In the assay comparing the serum samples of APS-1 patients after recovery 343 from COVID-19 with the prepandemic samples from these patients, noticeable decreases 344 in the signal for IgG against IFN-ω were observed: 32.8 (2019) None of the prepandemic sera from APS-1 patients (n=7) or pandemic sera from pa-349 tients not exposed to SARS-CoV-2 (n=3) showed reactivity above the cutoff value for ei-350 ther IgG or IgM against SARS-CoV-2 antigens. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted December 14, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 To assess the diagnostic accuracy of the microarray in a population that had not 394 been exposed to SARS-CoV-2, serum samples collected before May 2019 were used. Since perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted December 14, 2021. ; https://doi.org/10.1101/2021.12.13.21267509 doi: medRxiv preprint perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted December 14, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 et al. Early cross-coronavirus reactive signatures of humoral immunity against COVID-19 Co-infection of SARS-CoV-2 with other respiratory viruses and performance of lower respiratory tract samples for the 517 diagnosis of COVID-19 Autoantibodies against type I IFNs in patients with life-threatening COVID-19 Human Coronavirus-229E, -OC43, -NL63, and -HKU1 (Coronaviridae) Is preexisting immunity to seasonal coronaviruses limited to cross-reactivity with 524 SARS-CoV-2? A seroprevalence cross-sectional study in north-eastern France 527 Evolution of Early SARS-CoV-2 and Cross-Coronavirus Immunity Seven-month kinetics of SARS-CoV-2 antibodies and role of pre-existing antibodies to human coronaviruses Brown, I. Rates of Co-infection between SARS-CoV-2 and Other Respiratory 532 Viral pneumonia. The Lancet Autoantibody Detection in Patients with Autoimmune Polyglandular Syndromes Microarray analyzer based on wide field fluorescent microscopy with laser illumination and a device for 548 speckle suppression Simultaneous detection of seven staphylococcal enterotoxins: Development of 551 hydrogel biochips for analytical and practical application Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1 An Original ELISA-Based Multiplex Method for the Simultaneous Detection of 5 SARS-CoV-2 IgG 557 Analysis of SARS-CoV-2 antibodies in COVID-19 convalescent blood using a coronavirus antigen microarray Serologic Cross-Reactivity of SARS-CoV-2 with Endemic and Seasonal Betacoronaviruses Epitope-resolved profiling of the SARS-CoV-2 antibody response identifies cross-reactivity with endemic 589 human coronaviruses High prevalence of pre-existing serological cross-reactivity against severe acute respiratory syndrome coronavirus-2 592 (SARS-CoV-2) in sub-Saharan Africa Misdiagnosis of SARS-CoV-2: A Critical Review of the Influence of Sampling 595 and Clinical Detection Methods Prevalence of antibodies to four human coronaviruses is lower in nasal 600 secretions than in serum. Clinical and Vaccine Immunology Evaluation of Antibody Response in Symptomatic and Asymptomatic COVID-19 Patients and Diagnostic 603 Assessment of New IgM/IgG ELISA Kits Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1. The Journal of 606 experimental medicine 2021